SCYNEXIS Inc — Quarterly Cash Flow (NASDAQ:SCYX) | MetaTrader

Open full chart

Financials

Overview 성명 Statistics Dividends

Quarterly Annual

Total assets 99.04 M90.64 M67.92 M60.69 M51.07 M Total liabilities 40.51 M35.57 M17.38 M16.23 M14.64 M Total equity 58.53 M55.08 M50.53 M44.47 M36.43 M Total liabilities & shareholders' equities 99.04 M90.64 M67.92 M60.69 M51.07 M Total debt ————— Net debt —————

뉴스

SCYNEXIS, SCY-247 IV 제형 임상시험 첫 환자 투여

SCYNEXIS doses first patients in SCY-247 IV formulation trial

JERSEY CITY - FDA grants fast track and QIDP designations to SCYNEXIS drug

Scynexis receives 180-day extension from Nasdaq to meet listing requirements

트레비 테라퓨틱스, 데이비드 헤이스팅스를 CFO로 임명

SCYNEXIS, 항진균 연구로 연간 700만 달러 지원금 받아

SCYNEXIS receives $7 million annual grant for antifungal research

Guggenheim, SCYNEXIS 목표 주가 3달러로 하향 조정

Guggenheim lowers SCYNEXIS stock price target to $3 after GSK trial resolution

SCYNEXIS, GSK로부터 2,200만 달러 수령, MARIO 연구 종료

SCYNEXIS receives $22 million from GSK as MARIO study ends

Scynexis, GSK로부터 316억 원 수령, MARIO 연구 종료